CHI3L1 (Chitinase 3-like 1)

Gene expression analysis for both CLPs in white blood cells (WBCs) did not reveal statistical significance between CRC patients and controls. These findings enhance our understanding of the clinical relevance of these molecular signatures and support their potential application as biomarkers in CRC stratification.

Furthermore, Bortezomib suppressed CHI3L1 secretion in vitro and in vivo, inhibiting HCC lung metastasis. This study establishes CHI3L1 as a specific biomarker and a therapeutic target for HCC pulmonary metastasis.

In 3D GBM spheroid models, 10p significantly reduced tumor viability, mass, and migration, exceeding the efficacy of prior analogues. Collectively, these findings establish 10p as a potent CHI3L1 inhibitor with a superior pharmacokinetic profile and robust functional activity, marking it as a promising candidate for further GBM drug development.

Mechanistically, elevated CHI3L1 expression in the mammary epithelium enhanced neutrophil recruitment, which subsequently degraded the extracellular matrix and increased the number of circulating tumor cells. These findings reveal a key mechanism driving metastatic dissemination and argue that therapeutically targeting Chi3l1 could enhance anti-tumor immunity and suppress metastasis.

V-125 but not bexarotene reprograms tumor transcriptional programs and the immune landscape in an anti-tumor manner in the MMTV-neu mouse model and in in vitro models of HER2+ breast cancer. This highlights its promise as a selective RXR agonist with anti-tumor and immunomodulatory activity in HER2+ breast cancer.

Lead compound 9e (K d = 19.11 μM) reduced viability and STAT3 signaling in 3D GBM spheroids. These findings demonstrate the potential of reactivity-aware ultralarge screening to identify modulators of nonenzymatic, dynamic targets in complex cancer models.

This external validation confirms the seven-gene signature as a potential biomarker for predicting ICI efficacy in advanced sarcomas. Prospective studies are needed to determine the prognostic versus predictive value of SIGNIOS, refine its use across sarcoma subtypes, and explore its applicability in other tumor types.

Age, mechanical ventilation duration, APACHE Ⅱ score, and serum levels of PTX3, RBP, and STREM-1 are all predictors for the occurrence of VAP in older lung cancer patients. The nomogram model constructed based on these factors demonstrates acceptable predictive performance.

This study combined bioinformatics and network toxicology analysis strategies to identified hub genes potentially mediating the effects of PFDA/PFOS, providing evidences that PFDA/PFOS exposure have a potential association with GBM prognosis. Our study emphasized the need for further epidemiological and clinical studies.

In conclusion, bevacizumab remains an integral component of OC treatment. Future progress will depend on biomarker-driven, prospectively designed clinical trials and the integration of multi-omic data and machine learning approaches to enable precision application of anti-angiogenic strategies, maximising clinical benefit while minimising toxicity.

TEFT inhibits GBM progression by suppressing the TGF-β/SMAD2/3/STAT3/C1R axis, thereby attenuating EMT and reducing tumor aggressiveness. These findings uncover a novel mechanism of TEFT and identify C1R as a potential biomarker and therapeutic target for GBM.

These results highlight the potential of network-informed machine learning to identify subtle proteomic patterns and pathway-level dysregulation prior to clinical diagnosis. This proof-of-concept study supports further development of GNN approaches for early ovarian cancer detection and warrants validation in larger, independent cohorts.